Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread).
The purpose of this study is to find the highest dose of the investigational drug BCA101 that can be given safely alone and in combination with the immunotherapy drug pembrolizumab in patients with advanced lung cancer that cannot be cured with standard treatments. BCA101 is an antibody that targets two proteins involved in cancer growth called EGFR and TGF-beta. By blocking these proteins, BCA101 may interfere with the signals that spur cancer growth. 
Researchers in this study are comparing two different treatments for hairy cell leukemia. The people in this study have hairy cell leukemia that has not yet been treated. In addition, their leukemia has a genetic mutation (change) called BRAF V600E.
The purpose of this study is to find the highest dose of the investigational drug STK-012 that can be given safely in combination with pembrolizumab immunotherapy to people with solid tumors that have spread or come back despite prior treatment. STK-012 is a modified form of a protein called interleukin-2, which is normally made by the immune system. It may help to multiply and activate tumor-killing cells of the immune system.
Researchers want to see how well a new cellular immunotherapy works to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
The purpose of this study is to find the highest dose of the investigational drug RLY-2608 that can be used alone in people with advanced solid tumors and with fulvestrant in people with advanced breast cancer. Participants in this study will have cancers that contain a mutation in a gene called PIK3CA. Their cancers must have continued to grow despite treatment or be inoperable.
Researchers are doing this study to find the best dose of ziftomenib to give with standard chemotherapy in children and young adults with acute leukemia. The people in this study have acute leukemia that keeps growing or came back after treatment. In addition, their cancers have a mutation (change) in the KMT2A, NUP98, or NPM1 genes.
Umbilical card blood is rich in healthy, blood-forming cells (stem cells) that are very good at fighting blood cancers. Cord blood transplants (CBT) are a standard treatment for adults with blood cancers who lack a genetically matched stem cell donor. Cord blood is donated by a baby's mother at birth. CBT uses stem cells from cord blood collections to replace cells that have been destroyed by disease or anti-cancer treatment.
Researchers want to find the best dose of abemaciclib to combine with radiation therapy to treat advanced breast cancer. The people in this study have metastatic breast cancer that is fueled by estrogen or progesterone (hormone receptor-positive cancer). In addition, their breast cancer does not make a protein called HER2.
